Creo Medical receives King’s Award for Enterprise in Innovation

The company is to receive a King’s Award for Enterprise in Innovation, at an event held at Windsor Castle on 9 July 2024.

Established by Royal Warrant in 1965, The King's Awards for Enterprise is the UK’s most prestigious business awards to recognise and encourage achievements in the fields of Innovation, International Trade, Sustainable Development and Promoting Opportunity through social mobility. 

During the reception, His Majesty will meet Creo’s Chief Executive Officer, Craig Gulliford, as well as a diverse group of winners from across the United Kingdom, with recipients of the award able to use The King’s Awards emblem for the next five years on their products and to promote their services. 

Creo Medical Group plc is an innovative and growing medical technology company. It has developed CROMA, an advanced energy electrosurgical platform and a range of novel, miniaturised devices that are used through the small working channels of endoscopes, enabling the most minimally invasive surgery where operations are performed from inside the body. Creo’s Speedboat device harnesses CROMA's cutting and coagulation capabilities to remove cancerous and pre-cancerous growths and complex lesions in the bowel, oesophagus and stomach. By providing a solution that reduces the risks associated with conventional surgical procedures, Creo’s Speedboat allows clinicians to precisely lift, resect and coagulate tissue with a single device, removing lesions from within the gastrointestinal tract in one piece. This means patients can be treated as day cases under mild sedation instead of more invasive surgery requiring general anaesthetic and multiple days in hospital. 

Creo’s products deliver benefits to patients, reduces waiting lists, frees up resources, and significantly lowers hospital costs. NHS Supply Chain recently confirmed net cash savings of £687k were generated for an NHS Trust from 130 procedures using Creo’s core Speedboat technology. Creo’s technology is patent protected, and its devices are used daily across dozens of countries and in over 20 NHS hospitals.

Craig Gulliford, Chief Executive Officer of Creo Medical, said:

We are delighted to receive this award from His Majesty The King at a Royal reception in recognition of our team’s outstanding work, dedication and achievements towards innovation in healthcare. I would like to put on record my thanks to the whole team in their daily commitment to improving patient outcomes, cutting waiting times and saving the NHS money. Innovation has always been at the heart of Creo, and the increasing adoption of our pioneering technology by clinicians around of the world, reflects the significant benefits that innovation can bring to both patients and healthcare systems.

Posted 07/05/2024

For press enquiries please contact For all other enquiries please visit our Contact page.

Related News

NHS Supply Chain real-world data demonstrates substantial cash savings

Further news

15 May 2024

Full results - Final Results Strong revenue growth and significant commercial progress (9th May 2024)


13 May 2024

Directorate Changes - May 2024


02 May 2024

MicroBlate Flex in new clinical trial at Royal Brompton Hospital


24 April 2024

NHS Supply Chain real-world data demonstrates substantial cash savings


19 March 2024

Welsh Labour Leader visits Creo’s facilities


05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi


31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific


10 January 2024

First Use of Speedboat® UltraSlim in Latin America


13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch


01 November 2023

Speedboat® UltraSlim: US FDA Clearance